Top Markets
Coin of the day
National Graphite Corp. National Graphite Corp.

National Graphite Corp.

NGRC
Clasificación en acciones #35948
National Graphite Corp. (NGRC), operating through its subsidiary Biotech... National Graphite Corp. (NGRC), operating through its subsidiary Biotech Development Corp., functions as a biopharmaceutical enterprise specializing in risk and cost-sharing models. The company establishes partnerships with clinical-stage firms dedicated to developing novel biological entities or innovative therapeutic platforms. These collaborations aim to address a wide spectrum of health conditions, encompassing common illnesses, rare disorders, and those with significant unmet medical requirements. Among its key pipeline developments is ELAFIN, a drug candidate identified as a human-identical protein. ELAFIN is being developed specifically for the management of postoperative inflammatory complications. The advancement of ELAFIN is further supported by a collaboration agreement with Proteo Inc. Founded in 2006, National Graphite Corp. was formerly known as Lucky Boy Silver Corporation until it officially adopted its current name in May 2012. The company maintains its operational headquarters in Duesseldorf, Germany.
Precio por acción
$0.021
Última sincronización: 2026-08-13
Capitalización bursátil
$3.24M
Cambio (1 día)
0.00%
Cambio (1 año)
-46.15%
País
US
Comercio National Graphite Corp. (NGRC)
Ganancias de National Graphite Corp. (NGRC)
Ganancias en 2026 TTM: 0
Secondo gli ultimi rapporti finanziari di National Graphite Corp., gli utili attuali della società sono 0. Nel 2026, la società ha registrato un utile di 0, igual a agli utili del 2026, che erano di 0. Gli utili mostrati in questa pagina sono quelli prima degli interessi e delle imposte, ovvero EBIT.
Historial de ganancias de National Graphite Corp. desde 2026 hasta 2026
Ganancias al final de cada año
Año Ganancias Cambiar
Not enough data for the provided dates.
Ganancias de empresas similares o competidoras